56 related articles for article (PubMed ID: 4071064)
21. [Constitutional dysfunction of heparin cofactor II with a tendency for venous thrombosis].
Marbet GA; Zbinden B; Duckert F
Schweiz Med Wochenschr; 1988 Oct; 118(43):1586-8. PubMed ID: 3238395
[TBL] [Abstract][Full Text] [Related]
22. Neutralization of the anticoagulant effects of glycosaminoglycans by serum amyloid P component: comparison with other plasma and platelet proteins.
Williams EC; Huppert BJ; Asakura S
J Lab Clin Med; 1992 Jul; 120(1):159-67. PubMed ID: 1377216
[TBL] [Abstract][Full Text] [Related]
23. Interaction of heparin with histidine-rich glycoprotein and with antithrombin III.
Lijnen HR; van Hoef B; Collen D
Thromb Haemost; 1983 Aug; 50(2):560-2. PubMed ID: 6415849
[TBL] [Abstract][Full Text] [Related]
24. Heparin cofactor II determination--levels in normals and patients with hereditary antithrombin III deficiency and disseminated intravascular coagulation.
Tran TH; Duckert F
Thromb Haemost; 1984 Oct; 52(2):112-6. PubMed ID: 6395434
[TBL] [Abstract][Full Text] [Related]
25. A small fraction of dermatan sulfate with significantly increased anticoagulant activity was selected by interaction with the first complement protein.
Calabrese GC; Alberto MF; Tubio R; Marani MM; Fernández De Recondo ME; Lazzari M; Recondo EF
Thromb Res; 2004; 113(3-4):243-50. PubMed ID: 15140589
[TBL] [Abstract][Full Text] [Related]
26. Detection of histidine-rich glycoprotein and fibrinogen with nickel-enzyme conjugates: Purification of rabbit HRG.
Colwell M; Ahmed N; Butkowski R
Anal Biochem; 2017 May; 525():67-72. PubMed ID: 28235456
[TBL] [Abstract][Full Text] [Related]
27. Dermatan sulfate is a more potent inhibitor of clot-bound thrombin than unfractionated and low molecular weight heparins.
Bendayan P; Boccalon H; Dupouy D; Boneu B
Thromb Haemost; 1994 May; 71(5):576-80. PubMed ID: 8091383
[TBL] [Abstract][Full Text] [Related]
28. A heme- and metal-binding hexapeptide from the sequence of rabbit plasma histidine-rich glycoprotein.
Morgan WT; Deaciuc V; Riehm JP
J Mol Recognit; 1989 Nov; 2(3):122-6. PubMed ID: 2636901
[TBL] [Abstract][Full Text] [Related]
29. N-Acetylgalactosamine 4,6-O-sulfate residues mediate binding and activation of heparin cofactor II by porcine mucosal dermatan sulfate.
Halldórsdóttir AM; Zhang L; Tollefsen DM
Glycobiology; 2006 Aug; 16(8):693-701. PubMed ID: 16624894
[TBL] [Abstract][Full Text] [Related]
30. Chondroitin sulfate B and heparin mediate adhesion of Penicillium marneffei conidia to host extracellular matrices.
Srinoulprasert Y; Kongtawelert P; Chaiyaroj SC
Microb Pathog; 2006 Mar; 40(3):126-32. PubMed ID: 16455229
[TBL] [Abstract][Full Text] [Related]
31. Effect of dermatan sulfate and heparan sulfate on platelet activity compared to heparin.
Hoppensteadt DA; Walenga JM; Fareed J
Semin Thromb Hemost; 1991; 17 Suppl 1():60-4. PubMed ID: 2068572
[TBL] [Abstract][Full Text] [Related]
32. The interaction of beta 2 glycoprotein-I and heparin and its effect on beta 2 glycoprotein-I antiphospholipid antibody cofactor function in plasma.
McNally T; Cotterell SE; Mackie IJ; Isenberg DA; Machin SJ
Thromb Haemost; 1994 Oct; 72(4):578-81. PubMed ID: 7878636
[TBL] [Abstract][Full Text] [Related]
33. Histidine-rich glycoprotein plus zinc to neutralize heparin.
Fu CL; Horn MK
J Lab Clin Med; 2002 Apr; 139(4):211-7. PubMed ID: 12024108
[TBL] [Abstract][Full Text] [Related]
34. The heparin-binding site(s) of histidine-rich glycoprotein as suggested by sequence homology with antithrombin III.
Koide T; Foster D; Odani S
FEBS Lett; 1986 Jan; 194(2):242-4. PubMed ID: 3000827
[TBL] [Abstract][Full Text] [Related]
35. Proteolysis of histidine-rich glycoprotein in plasma and in patients undergoing thrombolytic therapy.
Smith A; Nuiry I; Morgan WT
Thromb Res; 1985 Dec; 40(5):653-61. PubMed ID: 2935971
[TBL] [Abstract][Full Text] [Related]
36. Histidine-rich glycoprotein inhibits contact activation of blood coagulation.
Vestergaard AB; Andersen HF; Magnusson S; Halkier T
Thromb Res; 1990 Dec; 60(5):385-96. PubMed ID: 2084959
[TBL] [Abstract][Full Text] [Related]
37. Neutralization of heparin activity by binding to human histidine-rich glycoprotein.
Lijnen HR; Hoylaerts M; Collen D
Thromb Res; 1983 Feb; 29(4):443-6. PubMed ID: 6857593
[No Abstract] [Full Text] [Related]
38. Purification of bovine histidine-rich glycoprotein.
Muldbjerg M; Schousboe I; Halkier T
Thromb Res; 1992 Mar; 65(6):815-9. PubMed ID: 1636169
[No Abstract] [Full Text] [Related]
39. Turnover of histidine-rich glycoprotein during heparin administration in man.
Lijnen HR; Collen D
Thromb Res; 1983 Jun; 30(6):671-6. PubMed ID: 6612690
[No Abstract] [Full Text] [Related]
40. Studies on the purification and characteristics of histidine-rich glycoprotein.
Sakuragawa N; Niwa M; Yamagishi R
Semin Thromb Hemost; 1985 Oct; 11(4):384-6. PubMed ID: 4071064
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
